People's Hospital of Xinjiang Uygur Autonomous Region
Objective: To evaluate the impact of enhanced recovery after surgery (ERAS)-based nursing intervention on venous thromboembolism (VTE) and lymphedema after radical hysterectomy for cervical cancer.
Methods: In this prospective randomized controlled trial, 160 patients scheduled for radical hysterectomy during September 2022-September 2024 were randomized to an ERAS group (n = 80) or a control group (n = 80). The control group received conventional perioperative care, while the ERAS group received a multimodal perioperative care protocol. Primary outcomes were the 6-month incidence of VTE and lower limb lymphedema. Secondary outcomes included recovery indicators, inflammatory and coagulation markers, quality of life [QoL; assessed by the Quality of Life Questionnaire-Core 30 (QLQ-C30)], and nursing satisfaction.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Xinjiang Uygur Autonomous Region
-
Ürümqi, Xinjiang Uygur Autonomous Region, China, 830000
- People's Hospital of Xinjiang Uygur Autonomous Region
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- . Pathologically confirmed cervical cancer (FIGO 2018) 2. Age 18-70 years 3. First-time radical hysterectomy 4. ASA physical status class I-II 5. Perioperative anticoagulant prophylaxis per hospital standards 6. Provision of informed consent
Exclusion Criteria:
- 1. Pre-existing lower extremity DVT, lymphedema, or severe varicose veins 2. Severe cardiac, hepatic, or renal dysfunction or coagulation disorders 3. History of psychiatric illness or communication barriers 4. Pregnant or lactating women
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Conventional Perioperative Care
The control group received conventional perioperative care.
This included routine preoperative education, fasting for 12 hours and no oral intake for 6 hours preoperatively, standard intraoperative fluid administration, postoperative patient-controlled analgesia pump, ambulation guided by traditional instructions (typically 1-2 days postoperatively), and initiation of liquid diet after passing flatus.
|
|
|
Experimental: ERAS Multimodal Pathway
In addition to conventional care, the ERAS group received a comprehensive intervention protocol based on ERAS principles, implemented by a dedicated ERAS nursing team. Details are as follows: Preoperative interventions: (1) Enhanced education and prehabilitation: Detailed explanation of the ERAS pathway, VTE and lymphedema prevention using graphics and videos. Instruction on ankle pump exercises and quadriceps isometric contractions. (2) Nutritional support: Nutritional risk assessment and provision of oral nutritional supplements if necessary. (3) Fasting management: No solid food for 6 hours, clear oral fluids (e.g., 200 mL of 10% glucose solution) allowed up to 2 hours preoperatively. Intraoperative interventions: (1) Thermoregulation: Use of forced-air warming blankets and fluid warmers to maintain core temperature > 36°C. (2) Restrictive fluid management: Goal-directed fluid therapy to avoid excessive infusion. (3) Minimally invasive and meticulous surgery: Encouragement of lapar |
In addition to conventional care, the ERAS group received a comprehensive intervention protocol based on ERAS principles, implemented by a dedicated ERAS nursing team. Details are as follows: Preoperative interventions: (1) Enhanced education and prehabilitation: Detailed explanation of the ERAS pathway, VTE and lymphedema prevention using graphics and videos. Instruction on ankle pump exercises and quadriceps isometric contractions. (2) Nutritional support: Nutritional risk assessment and provision of oral nutritional supplements if necessary. (3) Fasting management: No solid food for 6 hours, clear oral fluids (e.g., 200 mL of 10% glucose solution) allowed up to 2 hours preoperatively. Intraoperative interventions: (1) Thermoregulation: Use of forced-air warming blankets and fluid warmers to maintain core temperature > 36°C. (2) Restrictive fluid management: Goal-directed fluid therapy to avoid excessive infusion. (3) Minimally invasive and meticulous surgery: Encouragement of laparo |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Postoperative Venous Thromboembolism (VTE)
Prazo: 6 months after surgery
|
Composite incidence of deep vein thrombosis (DVT) of the lower extremities and pulmonary embolism (PE).
DVT is diagnosed by bilateral lower extremity venous color Doppler ultrasonography performed on postoperative day 3, before discharge, and at 1, 3, and 6 months postoperatively or when clinically indicated.
PE is evaluated by computed tomography pulmonary angiography (CTPA) when clinically suspected.
|
6 months after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Postoperative Lower Limb Lymphedema
Prazo: 6 months after surgery
|
Diagnosis based on International Society of Lymphology criteria (Grade I: pitting edema relieved by elevation; Grade II: non-pitting edema with tissue fibrosis; Grade III: elephantiasis).
Measured by bilateral calf circumference (thickest point) and thigh circumference (15 cm above patella).
|
6 months after surgery
|
|
Time to First Flatus
Prazo: Within 14 days after surgery (typically hours to days)
|
Number of hours from surgery completion to first passage of flatus, indicating recovery of gastrointestinal function.
|
Within 14 days after surgery (typically hours to days)
|
|
Time to First Defecation
Prazo: Within 14 days after surgery (typically days)
|
Number of hours from surgery completion to first bowel movement.
|
Within 14 days after surgery (typically days)
|
|
Time to First Ambulation
Prazo: Within 7 days after surgery
|
Number of days from surgery completion to the first time the patient walks independently (assisted or unassisted) outside the bed area.
|
Within 7 days after surgery
|
|
Postoperative Length of Hospital Stay
Prazo: At hospital discharge, assessed up to 4 weeks postoperatively
|
Total number of days from the date of surgery to the date of hospital discharge.
|
At hospital discharge, assessed up to 4 weeks postoperatively
|
|
Change in C-Reactive Protein (CRP)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in serum C-reactive protein (CRP) measured from fasting blood samples, reported in mg/L.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in D-Dimer (D-D)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in plasma D-dimer (D-D) measured from fasting blood samples, reported in mg/L.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in Platelet Count (PLT)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in platelet count (PLT) measured from complete blood count, reported in ×10⁹/L.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in Global Health Status / Quality of Life (QLQ-C30)
Prazo: Preoperative (baseline) vs. 6 months postoperatively
|
Change in the Global Health Status / Quality of Life subscale score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Minimum value: 0. Maximum value: 100.
Higher scores indicate better quality of life.
|
Preoperative (baseline) vs. 6 months postoperatively
|
|
Nursing Satisfaction
Prazo: At hospital discharge (postoperative day 7 to day 15)
|
Measured by the Newcastle Satisfaction with Nursing Scale (NSNS).
Categorized as: highly satisfied, moderately satisfied, or not satisfied.
Overall satisfaction rate = (highly satisfied + moderately satisfied) / total patients × 100%.
|
At hospital discharge (postoperative day 7 to day 15)
|
|
Change in White Blood Cell Count (WBC)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in white blood cell count (WBC) measured from fasting blood samples, reported in ×10⁹/L.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in Prothrombin Time (PT)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in prothrombin time (PT) measured from fasting blood samples, reported in seconds.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in Hemoglobin (Hb)
Prazo: Preoperative (baseline) vs. Postoperative day 3
|
Change in hemoglobin (Hb) measured from complete blood count, reported in g/L.
|
Preoperative (baseline) vs. Postoperative day 3
|
|
Change in Functional Scales (QLQ-C30)
Prazo: Preoperative (baseline) vs. 6 months postoperatively
|
Change in the Functional Scales composite score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Minimum value: 0. Maximum value: 100.
Higher scores indicate better functional status.
|
Preoperative (baseline) vs. 6 months postoperatively
|
|
Change in Symptom Scales (QLQ-C30)
Prazo: Preoperative (baseline) vs. 6 months postoperatively
|
Change in the Symptom Scales composite score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Minimum value: 0. Maximum value: 100.
Higher scores indicate worse symptom burden.
|
Preoperative (baseline) vs. 6 months postoperatively
|
|
Change in Single Items (QLQ-C30)
Prazo: Preoperative (baseline) vs. 6 months postoperatively
|
Change in the Single Items score (including dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Minimum value: 0. Maximum value: 100.
Higher scores indicate worse symptom burden or greater financial difficulty.
|
Preoperative (baseline) vs. 6 months postoperatively
|
|
Change in Total Score (QLQ-C30)
Prazo: Preoperative (baseline) vs. 6 months postoperatively
|
Change in the total score from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
Minimum value: 0. Maximum value: 100.
Higher scores indicate better overall quality of life.
|
Preoperative (baseline) vs. 6 months postoperatively
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças Vasculares
- Doenças cardiovasculares
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças uterinas
- Doenças Genitais Femininas
- Embolia e Trombose
- Neoplasias Genitais Femininas
- Doenças Linfáticas
- Doenças do colo do útero
- Neoplasias uterinas
- Tromboembolismo
- Doenças hemic e linfáticas
- Linfedema
- Neoplasias do colo uterino
- Tromboembolismo venoso
Outros números de identificação do estudo
- KY2022080503
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .